Author:
Michel Maurice Stephan,Gschwend Jürgen E.,Wullich Bernd,Krege Susanne,Bolenz Christian,Merseburger Axel S.,Krabbe Laura-Maria,Schultz-Lampel Daniela,König Frank,Haferkamp Axel,Hadaschik Boris
Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Ahlering T, Huynh LM, Kaler KS et al (2019) Unintended consequences of decreased PSA-based prostate cancer screening. World J Urol 37:489–496
2. Alberts AR, Roobol MJ, Verbeek JFM et al (2019) Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol 75:310–318
3. Ankerst DP, Straubinger J, Selig K et al (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197–203
4. Boschheidgen M, Albers P, Schlemmer HP et al (2024) Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 85:105–111
5. Bratt O, Godtman RA, Jiborn T et al (2023) Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. Eur Urol